Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23778493 | 0.98 | AKR1C1 (0.52) | AKR1C1ALDH1A1LMNAKMT2AVNN1 | |
| SCHEMBL9338162 | 0.93 | AKR1C1 (0.65) | AKR1C1ALDH1A1LMNAKMT2AVNN1 | |
| SCHEMBL17896072 | 0.91 | AKR1C1 (0.62) | AKR1C1ALDH1A1LMNAKMT2AVNN1 | |
| SCHEMBL8302463 | 0.89 | ITGA4 (0.46) | AKR1C1ALDH1A1LMNAKMT2AVNN1 | |
| Hydrochloric Acid SCHEMBL8350428 | 0.87 | ITGA4 (0.45) | AKR1C1ALDH1A1LMNAKMT2AVNN1 | |
| SCHEMBL3441871 | 0.86 | ALDH1A1 (0.54) | AKR1C1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL27953257 | 0.86 | ITGA4 (0.48) | AKR1C1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL10002454 | 0.84 | OPRM1 (0.49) | ALDH1A1LMNAKMT2AVNN1MEN1 | |
| SCHEMBL16700345 | 0.83 | ALDH1A1 (0.42) | AKR1C1ALDH1A1LMNAKMT2AVNN1 | |
| SCHEMBL6422989 | 0.80 | CHRM2 (0.59) | ALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528798-B2 | Compound for crop protectant | LG CHEM, LTD. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| US-20240246945-A1 | NOVEL COMPOUND FOR CROP PROTECTANT | LG CHEM, LTD. (KR) | 2024-07-25 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-110088089-B | Benzyl amino pyridyl cyclopropane carboxylic acid, pharmaceutical composition and application thereof | 勃林格殷格翰国际有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-111032647-B | Lysophosphatidic acid receptor 1 (LPAR 1) inhibitor compounds | 伊莱利利公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| CN-104927879-A | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | JSR CORP | 2015-09-23 | — | — | CN | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2834238-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | Pfizer Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| CN-104334557-A | Diacylglycerol acyltransferase 2 inhibitors | PFIZER | 2015-02-04 | — | — | CN | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2013150416-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2012164085-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-12-06 | — | — | WO | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | AKR1C1 304/4885ALDH1A1 1726/4885LMNA 1162/4885 |
| US-20240246945-A1 | NOVEL COMPOUND FOR CROP PROTECTANT | KEAP1, BROX, GPX1 | AKR1C1 1123/4885ALDH1A1 2249/4885LMNA 2246/4885 |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, PLAAT2 | AKR1C1 1447/4885ALDH1A1 453/4885LMNA 3540/4885 |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | AKR1C1 494/4885ALDH1A1 1649/4885LMNA 3849/4885 |
| US-12528798-B2 | Compound for crop protectant | CBR1, CBR3, GSTO1 | AKR1C1 1252/4885ALDH1A1 2445/4885LMNA 1868/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | AKR1C1 3944/4885ALDH1A1 2147/4885LMNA 4778/4885 |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | CNR1, CNR2, MAG | AKR1C1 1581/4885ALDH1A1 2505/4885LMNA 1329/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | AKR1C1 304/4885ALDH1A1 1726/4885LMNA 1162/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | AKR1C1 304/4885ALDH1A1 1726/4885LMNA 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.